Combination drug therapy demonstrates potential to treat AMD subtype
Data from patients with a subtype of AMD enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ...
Tag: OPT-302
Opthea announces Australian trial sites for its novel wet AMD treatment
Melbourne-based biopharmaceutical company Opthea has opened clinical trial sites in Australia, including in East Melbourne and Rowville, for patients to ...
Opthea treats first patient in Phase 3 nAMD trial
The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular ...
Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ...
Opthea meets US and European regulators over Phase 3 trial
A Melbourne-based drug company is one step closer to starting Phase 3 clinical trials and pre-commercial development of its novel ...
Opthea becomes ASX top 300 company
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met ...